Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

363 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risperidone in the treatment of acute schizophrenia.
Raedler TJ, Schreiner A, Naber D, Wiedemann K. Raedler TJ, et al. Among authors: schreiner a. J Clin Psychopharmacol. 2004 Jun;24(3):335-8. doi: 10.1097/01.jcp.0000126660.50788.ef. J Clin Psychopharmacol. 2004. PMID: 15118488
Early onset of treatment effects with oral risperidone.
Raedler TJ, Schreiner A, Naber D, Wiedemann K. Raedler TJ, et al. Among authors: schreiner a. BMC Psychiatry. 2007 Jan 19;7:4. doi: 10.1186/1471-244X-7-4. BMC Psychiatry. 2007. PMID: 17239237 Free PMC article. Clinical Trial.
Efficacy and safety of risperidone in the treatment of elderly patients suffering from organic brain disease (organic brain syndrome): results from a double-blind, randomized, placebo-controlled clinical trial.
Naber D, Greenspan A, Schreiner A. Naber D, et al. Among authors: schreiner a. Psychopharmacology (Berl). 2007 May;191(4):1027-9. doi: 10.1007/s00213-007-0747-6. Epub 2007 Feb 27. Psychopharmacology (Berl). 2007. PMID: 17333131 Clinical Trial. No abstract available.
Treatment response and tolerability with once-monthly paliperidone palmitate initiated shortly after hospital admission in patients with schizophrenia.
Hargarter L, Lahaye M, Cherubin P, Lambert M, Swarz M, Joldygulov G, Vischia F, Chomskaya V, Bozikas VP, Tsapakis EM, Schreiner A. Hargarter L, et al. Among authors: schreiner a. World J Biol Psychiatry. 2018;19(sup3):S147-S157. doi: 10.1080/15622975.2017.1315176. Epub 2017 Jun 8. World J Biol Psychiatry. 2018. PMID: 28594264
Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial.
Gaebel W, Schreiner A, Bergmans P, de Arce R, Rouillon F, Cordes J, Eriksson L, Smeraldi E. Gaebel W, et al. Among authors: schreiner a. Neuropsychopharmacology. 2010 Nov;35(12):2367-77. doi: 10.1038/npp.2010.111. Epub 2010 Aug 4. Neuropsychopharmacology. 2010. PMID: 20686456 Free PMC article. Clinical Trial.
Nurses' perceptions of medication adherence in schizophrenia: results of the ADHES cross-sectional questionnaire survey.
Emsley R, Alptekin K, Azorin JM, Cañas F, Dubois V, Gorwood P, Haddad PM, Naber D, Olivares JM, Papageorgiou G, Roca M, Thomas P, Hargarter L, Schreiner A; EMEA ADHES group. Emsley R, et al. Among authors: schreiner a. Ther Adv Psychopharmacol. 2015 Dec;5(6):339-50. doi: 10.1177/2045125315612013. Ther Adv Psychopharmacol. 2015. PMID: 26834967 Free PMC article.
363 results